Bragar Eagel & Squire, P.C. said a class action lawsuit has been filed against Replimune Group Inc. in the United States District Court for the District of Massachusetts on behalf of investors who purchased or otherwise acquired Replimune securities between October 20, 2025 and April 10, 2026. The firm said investors have until October 5, 2026 to ask the court to appoint them lead plaintiff. The complaint alleges Replimune made materially false or misleading statements, or omitted material adverse information, tied to its Biologics License Application, or BLA (application for approval of a biologic drug). The allegations include that study design concerns previously communicated by the FDA (U.S. drug regulator) were not addressed, that the company submitted data from an early unplanned analysis of RP1-104 involving 40 patients, or 10% of the planned 400-patient enrollment, and that deficiencies in RPL-001-16 and RP1-104 were likely to lead the FDA to reject the BLA. Bragar Eagel & Squire is inviting investors who suffered losses, long-term stockholders, or people with relevant information to contact Brandon Walker or Melissa Fortunato to discuss their options.